Mission Pharmacal Header

Mission Pharmacal Header

X

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Filters

×

FILTER:

filter

News Type

filter

Company

filter

Product Type

filter

Deal Size

filter

Upfront Payment

Active Filter(s):

Filters

Reset Filter

All Developments

Product Type

Companies

[{"company":"Foamix Pharmaceuticals","sponsor":"Cutia Therapeutics","pharmaFlowCategory":"D","amount":"$11.0 million ","upfrontCash":"$10.0 million","newsHeadline":"Menlo Therapeutics and Cutia Therapeutics ink License Agreement for AMZEEQ\u2122 and Approved Topical Minocycline Products in Greater China","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Approved","country":"ISRAEL","productType":"Small molecule","productStatus":"Approved","date":"April 2020","url1":"","url2":"","graph1":"Small molecule","graph2":"Foamix Pharmaceuticals"},{"company":"Luminera","sponsor":"Innovative Luminera","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Allergan Aesthetics, an AbbVie Company, Acquires Innovative Luminera Dermal Filler Business","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Approved","country":"ISRAEL","productType":"Small molecule","productStatus":"Approved","date":"October 2020","url1":"","url2":"","graph1":"Small molecule","graph2":"Luminera"},{"company":"Sol-Gel Technologies","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sol-Gel Technologies Announces U.S. Commercial Partner Galderma to Promote TWYNEO\u00ae at the American Academy of Dermatology Annual Meeting to be Held March 25-29 in Boston, MA","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Approved","country":"ISRAEL","productType":"Small molecule","productStatus":"Approved","date":"March 2022","url1":"","url2":"","graph1":"Small molecule","graph2":"Sol-Gel Technologies"},{"company":"Sol-Gel Technologies","sponsor":"Galderma","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sol-Gel Technologies and Galderma Announce FDA Approval of EPSOLAY\u00ae","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Approved","country":"ISRAEL","productType":"Small molecule","productStatus":"Approved","date":"April 2022","url1":"","url2":"","graph1":"Small molecule","graph2":"Sol-Gel Technologies"},{"company":"Sol-Gel Technologies","sponsor":"Jefferies LLC","pharmaFlowCategory":"D","amount":"$23.0 million","upfrontCash":"Undisclosed","newsHeadline":"Sol-Gel Announces Pricing of Public Offering of Ordinary Shares and Warrants to Purchase Ordinary Shares","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Approved","country":"ISRAEL","productType":"Small molecule","productStatus":"Approved","date":"February 2020","url1":"","url2":"","graph1":"Small molecule","graph2":"Sol-Gel Technologies"}]

Sol-Gel Technologies

Contact Supplier

Upload your Marketing & Sales content on your company Virtual Booth, click HERE

Post an Enquiry

Post an Enquiry

Digital Content

Sol-Gel Technologies and Galderma Announce FDA Approval of EPSOLAY®

Details:

Approval of EPSOLAY (benzoyl peroxide) is supported by data from Phase 3 trial, which demonstrated reduction in inflammatory lesions of rosacea by nearly 70% by end of both 12-week trials vs. 38-46% with vehicle.

Lead Product(s): Benzoyl Peroxide

Therapeutic Area: Dermatology Product Name: Epsolay

Highest Development Status: Approved Product Type: Small molecule

Partner/Sponsor/Collaborator: Galderma

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable April 25, 2022

ASK
US

Upload
your Pipeline Activity

Sol-Gel Technologies

Contact Supplier

Upload your Marketing & Sales content on your company Virtual Booth, click HERE

Post an Enquiry

Post an Enquiry

Digital Content

Sol-Gel Technologies Announces U.S. Commercial Partner Galderma to Promote TWYNEO® at the American Academy of Dermatology Annual Meeting to be Held March 25-29 in Boston, ...

Details:

TWYNEO is a topical cream containing a fixed‑dose combination of tretinoin, 0.1%, and benzoyl peroxide, 3%, for the treatment of acne vulgaris in adults and pediatric patients nine years of age and older.

Lead Product(s): Tretinoin,Benzoyl Peroxide

Therapeutic Area: Dermatology Product Name: Twyneo

Highest Development Status: Approved Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable March 25, 2022

ASK
US

Upload
your Pipeline Activity

Luminera

Contact Supplier

Upload your Marketing & Sales content on your company Virtual Booth, click HERE

Post an Enquiry

Post an Enquiry

Digital Content

Allergan Aesthetics, an AbbVie Company, Acquires Innovative Luminera Dermal Filler Business

Details:

Allergan Aesthetics will acquire Luminera's full dermal filler portfolio and R&D pipeline further enhancing Allergan Aesthetics' leading dermal filler portfolio with its JUVÉDERM® collection of fillers.

Lead Product(s): Hyaluronic Acid,Calcium Hydroxyapatite

Therapeutic Area: Dermatology Product Name: HArmonyCa

Highest Development Status: Approved Product Type: Small molecule

Partner/Sponsor/Collaborator: Innovative Luminera

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Acquisition October 07, 2020

ASK
US

Upload
your Pipeline Activity

Foamix Pharmaceuticals

Contact Supplier

Upload your Marketing & Sales content on your company Virtual Booth, click HERE

Post an Enquiry

Post an Enquiry

Digital Content

Menlo Therapeutics and Cutia Therapeutics ink License Agreement for AMZEEQ™ and Approved Topical Minocycline Products in Greater China

Details:

Cutia will have an exclusive license to obtain regulatory approval and sell AMZEEQ. Foamix is to supply Cutia with the finished licensed products for clinical and commercial use.

Lead Product(s): Minocycline Hydrochloride

Therapeutic Area: Dermatology Product Name: Undisclosed

Highest Development Status: Approved Product Type: Small molecule

Partner/Sponsor/Collaborator: Cutia Therapeutics

Deal Size: $11.0 million Upfront Cash: $10.0 million

Deal Type: Licensing Agreement April 23, 2020

ASK
US

Upload
your Pipeline Activity

Sol-Gel Technologies

Contact Supplier

Upload your Marketing & Sales content on your company Virtual Booth, click HERE

Post an Enquiry

Post an Enquiry

Digital Content

Sol-Gel Announces Pricing of Public Offering of Ordinary Shares and Warrants to Purchase Ordinary Shares

Details:

The Company intends to use the net proceeds from the Offering to fund pre-commercialization and launch activities for Epsolay® and Twyneo®, research and development activities and the remainder for working capital and other general corporate purposes.

Lead Product(s): Benzoyl Peroxide

Therapeutic Area: Dermatology Product Name: Epsolay

Highest Development Status: Approved Product Type: Small molecule

Partner/Sponsor/Collaborator: Jefferies LLC

Deal Size: $23.0 million Upfront Cash: Undisclosed

Deal Type: Public Offering February 14, 2020

ASK
US

Upload
your Pipeline Activity

POST ENQUIRY